Eqis Capital Management Inc. lowered its holdings in Amgen, Inc. (NASDAQ:AMGN) by 38.2% in the 1st quarter, Holdings Channel reports. The firm owned 23,187 shares of the medical research company’s stock after selling 14,317 shares during the period. Eqis Capital Management Inc.’s holdings in Amgen were worth $4,405,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of AMGN. Oregon Public Employees Retirement Fund raised its stake in shares of Amgen by 20,103.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 31,424,215 shares of the medical research company’s stock worth $161,000 after purchasing an additional 31,268,677 shares during the last quarter. Norges Bank purchased a new stake in Amgen during the fourth quarter valued at $1,283,248,000. BlackRock Inc. increased its position in Amgen by 2.0% during the fourth quarter. BlackRock Inc. now owns 46,127,396 shares of the medical research company’s stock valued at $8,979,621,000 after acquiring an additional 906,568 shares during the last quarter. Geode Capital Management LLC increased its position in Amgen by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock valued at $1,720,250,000 after acquiring an additional 482,760 shares during the last quarter. Finally, Epoch Investment Partners Inc. increased its position in Amgen by 536.5% during the fourth quarter. Epoch Investment Partners Inc. now owns 524,376 shares of the medical research company’s stock valued at $102,080,000 after acquiring an additional 441,995 shares during the last quarter. Hedge funds and other institutional investors own 80.65% of the company’s stock.

Shares of AMGN opened at $171.30 on Thursday. The company has a debt-to-equity ratio of 2.71, a current ratio of 2.77 and a quick ratio of 2.53. The stock has a market capitalization of $103.09 billion, a price-to-earnings ratio of 11.90, a P/E/G ratio of 2.24 and a beta of 1.15. Amgen, Inc. has a 52 week low of $166.30 and a 52 week high of $210.19.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, April 30th. The medical research company reported $3.56 EPS for the quarter, topping analysts’ consensus estimates of $3.45 by $0.11. The business had revenue of $5.56 billion during the quarter, compared to analysts’ expectations of $5.55 billion. Amgen had a return on equity of 71.02% and a net margin of 34.00%. The business’s quarterly revenue was up .1% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.47 earnings per share. As a group, research analysts anticipate that Amgen, Inc. will post 13.94 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a yield of 3.39%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s payout ratio is 40.28%.

AMGN has been the subject of a number of research reports. Mizuho reiterated a “buy” rating and set a $211.00 price objective on shares of Amgen in a research report on Wednesday, February 13th. BidaskClub cut Amgen from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 29th. Oppenheimer set a $224.00 price objective on Amgen and gave the company a “buy” rating in a research report on Sunday, January 27th. Cowen reiterated a “buy” rating and set a $234.00 price objective on shares of Amgen in a research report on Tuesday, February 26th. Finally, Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $215.00 price objective for the company in a research report on Tuesday, April 2nd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $209.30.

In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $193.18, for a total value of $386,360.00. Following the completion of the sale, the director now owns 15,092 shares in the company, valued at $2,915,472.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In the last 90 days, insiders sold 6,000 shares of company stock valued at $1,115,580. Company insiders own 0.25% of the company’s stock.

WARNING: “Amgen, Inc. (AMGN) Stake Decreased by Eqis Capital Management Inc.” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://theolympiareport.com/2019/05/23/amgen-inc-amgn-stake-decreased-by-eqis-capital-management-inc.html.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

See Also: What is a stock split?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.